Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia (RE-AFFIRM)
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia
Sponsor: Tonix Pharmaceuticals, Inc.
Terminated
For business reason unrelated to safety or tolerability,Tonix discontinued this study.
Other terminated trials from Tonix Pharmaceuticals, Inc.
More terminations from Tonix Pharmaceuticals, Inc.
Other Fibromyalgia trials with similar outcome
A PHASE3 clinical study on Fibromyalgia and Muscular Diseases, this trial is terminated or withdrawn. The trial is conducted by Tonix Pharmaceuticals, Inc. and has accumulated 13 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Mar 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Mar 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
▶ Show 8 earlier versions
-
Dec 2021 — Apr 2022 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Terminated PHASE3
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE3
-
Aug 2017 — May 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jul 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tonix Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .